HMGB1 and ovarian carcinoma: Inhibits HMGB1-TLR4 signaling in M2 macrophages, antagonizing their pro-tumor functions. Reduces M2 markers (e.g., TGF-β, MMP-9) and ovarian cancer cell proliferation, migration, and invasion facilitated by M2 macrophages.